Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical-trial disclosures, patent expiration timelines, or royalty obligations inside Pfizer’s massive SEC filings can feel like searching for a single molecule in a lab. Each 300-page Pfizer annual report 10-K simplified contains dozens of drug-pipeline tables, while every Pfizer quarterly earnings report 10-Q filing updates revenue by therapeutic area and COVID-19 vaccine demand. Add frequent 8-Ks announcing material study results and the picture grows increasingly complex for investors.
That’s where Stock Titan’s AI steps in. Our engine delivers real-time alerts and plain-English summaries the moment a new document hits EDGAR, turning Pfizer SEC filings explained simply into actionable insight. Need Pfizer insider trading Form 4 transactions? You’ll see executive stock trades within minutes, with context on trial milestones. Curious about Pfizer proxy statement executive compensation? Our AI highlights pay tied to oncology breakthroughs. Even Pfizer 8-K material events explained are broken down, so you understand why a Phase 3 success moves the stock.
Whether you’re comparing R&D spend across quarters, tracking Pfizer Form 4 insider transactions real-time, or performing Pfizer earnings report filing analysis, the platform ties each form to the questions professionals actually ask. Use the searchable dashboard to pinpoint:
- Segment revenue trends buried in 10-Qs
- Patent-cliff discussions inside the 10-K
- Pfizer executive stock transactions Form 4 around FDA decisions
Understanding Pfizer SEC documents with AI means no more manual page-turning—just concise insights on drug safety updates, collaboration economics, and global sales dynamics.
Albert Bourla, Pfizer Inc. Chairman & CEO, acquired 24 phantom stock units on 08/15/2025. Each unit represents one phantom share of common stock and the units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. The units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account at any time. Following the reported transaction, the reporting person beneficially owns 730,477 shares (direct).
Pfizer Inc. (PFE) – Form 4 insider filing shows Chairman & CEO Albert Bourla acquired a de minimis 26 phantom stock units on 31-Jul-2025 through the company’s Non-Funded Deferred Compensation and Supplemental Savings Plan (SSP).
• Transaction code: A (acquisition).
• Unit price: $23.29.
• Total value: ≈ $606.
• Post-transaction holdings: 731,620 phantom stock units, held directly (D).
Phantom units are cash-settled and do not alter the public share count; the participant may transfer them into another investment option at any time. No common stock transactions were reported in Table I.
Materiality: The addition represents less than 0.01 % of Bourla’s existing derivative position and has no discernible impact on Pfizer’s capital structure or governance.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
